ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
Melissa Lynne JohnsonArkadiusz Z DudekAmmar SukariJustin CallPaul R KunkKarl LewisJustin F GainorJohn SarantopoulosPatrice LeeAdele GoldenAllison HarneyS Michael RothenbergYuanyuan ZhangJonathan Wade GoldmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Although limited clinical benefit was observed, ARRY-382 plus pembrolizumab was well tolerated.
Keyphrases